NEW YORK (GenomeWeb) – MRM and Biodesix said today that they are partnering to develop mass spectrometry-based assays for lung cancer.
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI technologies to develop blood-based tests for lung cancer.
MRM's iMALDI method uses upfront enrichment of target proteins followed by MALDI mass spec analysis of those proteins.
"Examining a patient’s genomic data has advanced targeted therapies. However, proteins are the targets of most drugs and hold the key to unlocking the promise of precision medicine," Christoph Borchers, CSO for MRM Proteomics, said in a statement. "Biodesix is a natural partner for our proteomic technology because they are committed to a multi-omics approach to reveal a more complete molecular profile of lung cancer in the body. We believe that this partnership will produce much-needed advances in the proteomic space and lead to more precise lung cancer diagnostic tools that can help guide treatment decisions."
"Elevating the importance of proteomics in revealing the full complexity of cancer is critical to getting patients the right treatment at the right time. MRM Proteomics is a leader in providing technologies that can help us unleash this potential," said Scott Hutton, COO for Biodesix.
Financial and other terms of the agreement were not disclosed.